SHANGHAI, Sept. 17, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced an...
Hence then, the article about wuxi xdc out licenses wuxitecan 2 payload linker technology platform to ona therapeutics to advance novel adc research and development was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( WuXi XDC Out-Licenses WuXiTecan-2 Payload-Linker Technology Platform to Ona Therapeutics to Advance Novel ADC Research and Development )
Also on site :
- Walmart’s $18 Pearl Drop Earrings With Swarovski Crystals Are a Quiet-Luxury Staple That ‘Look Very Expensive’
- Bran Flakezz on Winning ‘Unwell Summer Games,’ His Future With Reality TV and the Alex Cooper-Alix Earle Drama
- Robert De Niro’s Best Movie According to Critics Is a Surprising 1985 Cult Classic With a Kate Bush Connection